Aggressive Lymphomas
Feature
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.
From the Journals
Researchers characterize new subtype of high-grade DLBCL
Patients with this subtype had distinct molecular features and poor prognosis.
From the Journals
Few DLBCL patients benefit from nivolumab
Just 10 of 121 patients responded to nivolumab in a phase 2 trial and researchers aren’t sure why this particular group of patients responded.
From the Journals
Anthracyclines, bendamustine are options for grade 3A follicular lymphoma
A CVP chemotherapy regimen performed poorly compared with anthracycline-based chemotherapy in advanced stage follicular lymphoma.
From the Journals
Ibrutinib-MTX-rituximab combo shows promise in CNS lymphoma
The researchers proposed an 840-mg dose of ibrutinib in future studies.
Conference Coverage
Applying ECHELON-2 results to clinical practice
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
From the Journals
Imaging, radiotherapy clarified in new PMBCL guidelines
The new good practice paper from the British Society for Haematology also addresses fertility preservation.
News
Combo treatment may improve quality of life in CTCL
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...
Conference Coverage
Are single agents better than chemo for relapsed/refractory PTCL?
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
Video
Four-drug combo shows durable responses in relapsed/refractory lymphomas
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.